| Trial ID: | L0253 |
| Source ID: | NCT02049736
|
| Associated Drug: |
Telbivudine
|
| Title: |
Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Hepatitis B
|
| Interventions: |
DRUG: Telbivudine
|
| Outcome Measures: |
Primary: change in estimated glomerular filtration rate, every 3 months for 5 years | Secondary: proteinuria, every 3 months for 5 years|HBV DNA level, every 6 months for 5 years
|
| Sponsor/Collaborators: |
Sponsor: Chinese University of Hong Kong
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-12
|
| Completion Date: |
2015-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-07-28
|
| Locations: |
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong
|
| URL: |
https://clinicaltrials.gov/show/NCT02049736
|
